Safety and Tolerability of Adaptive Escalating Multiple Doses (Three Times Daily) of a Soluble Guanylate Cyclase (sGC) Activator Inhale, BAY 1211163, as Inhalation in Intubated and Mechanically Ventilated Adult Patients With Moderate and Severe Acute Respiratory Distress Syndrome (ARDS). A Pilot (Phase Ib), First in Patient, Open Label Study
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Bayer
- 入组人数
- 16
- 试验地点
- 4
- 主要终点
- Numbers of participants with treatment emergent adverse events (TEAEs)
研究概览
简要总结
With this study researchers want to find the highest safe dose of the soluble Guanylate Cyclase (sGC) Activator, BAY 1211163 and how safe and well the study drug works. Furthermore researchers want to gather information on the way the body absorbs, distributes and gets rid of the study drug given as increasing multiple doses by inhalation to patients who cannot breathe by their own and suffer from a type of lung failure that causes fluid to build up in the lungs making breathing difficult (ARDS)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Intubated, mechanically ventilated moderate or severe ARDS patients [diagnosed according to Berlin definition of ARDS, including PEEP ≥ 5 cmH2O, X-ray, with PaO2/FiO2 between 80 and 200 mmHg (inclusive).
- •Initial diagnosis of ARDS prior to study inclusion, confirmation of ongoing moderate or severe ARDS with PaO2/FiO2 between 80 and 200 mmHg (inclusive) during this time under maintained invasive mechanical ventilation.
- •Hypoxemia with PaO2/FiO2 between 80 and 200 mmHg (inclusive) maintained for at least 8 hours (recommend to be 12 hours) after screening, despite consent to follow recommendation on ventilator strategy and PEEP management.
- •Time from intubation must be ≤ 96h.
- •Male and non-pregnant female.
- •Informed consent of capable patient or, in case of patient being incapable of giving informed consent, consent for study inclusion will be sought according to applicable laws and regulations.
排除标准
- •PaO2/FiO2 > 200 mmHg or < 80 mmHg at time of evaluation for inclusion.
- •Moribund participants not expected to survive 24 hours (clinical decision).
- •Expected duration of invasive mechanical ventilation less than 96 hours (clinical decision).
- •History of pneumectomy or lung transplant.
- •Current lung malignancy (including lung metastasis), or other malignancy requiring chemotherapy or radiation within the last month.
- •History of chronic kidney disease and requiring renal replacement therapy dialysis at screening and/or baseline.
- •Chronic liver disease Child-Pugh Class B and C.
- •Hypoalbuminemia - serum albumin < 2.0 g/dL.
- •Acute left ventricular failure and/or Left Ventricular Ejection Fraction < 30 %.
- •Severe bronchopulmonal fistula.
- •Clinical suspicion of pulmonary veno-occlusive disease.
- •Heart right-sided endocarditis, tumors or mass.
- •Rescue procedures already initiated at screening and/or Day
- •Use of co-medications involving moderate and strong inhibitors for CYP2C8 liver enzymes one week before assignment to intervention or during intervention.
- •Off-label use of medication to treat Coronavirus SARS-CoV-2 virus unless recommended by scientific guidelines and accepted by DMC, investigator and sponsor.
- •Plan to participate or past participation (within 30 days prior to Study Day 1) in other interventional studies.
研究组 & 干预措施
BAY1211163
Adult patients with moderate or severe Acute Respiratory Distress Syndrome (ARDS) diagnosis before study inclusion will receive BAY1211163.
干预措施: BAY1211163 (Drug)
结局指标
主要结局
Numbers of participants with treatment emergent adverse events (TEAEs)
时间窗: Up to 9 days
Numbers of participants with dose limiting events (DLEs)
时间窗: Day 1 to 7 (may include Day 8)
A dose limiting event is defined as any of the TEAEs occurring during dosing with BAY1211163 and regarded by the investigators to be related to BAY1211163.
次要结局
- Values of oxygenation index (OI)(Up to 28 days)